Akari Therapeutics (FRA:CLA) Accounts Payable & Accrued Expense : €3.97 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Accounts Payable & Accrued Expense?

Akari Therapeutics's quarterly accounts payable & accrued expense declined from Jun. 2023 (€3.17 Mil) to Dec. 2023 (€2.80 Mil) but then increased from Dec. 2023 (€2.80 Mil) to Mar. 2024 (€3.97 Mil).

Akari Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 (€4.40 Mil) to Dec. 2022 (€2.52 Mil) but then increased from Dec. 2022 (€2.52 Mil) to Dec. 2023 (€2.80 Mil).

Akari Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Akari Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Accounts Payable & Accrued Expense Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4.91

4.29

4.40

2.52

2.80

Akari Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.52	-	3.17	2.80	3.97

Akari Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Akari Therapeutics (FRA:CLA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.